Spyre Therapeutics, Inc. SYRE Change in Other Liabilities
Change in Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherAccountsPayable.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s change in other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s change in other liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported change in other liabilities of $36K in Q1 2026.
- How has Spyre Therapeutics, Inc.'s change in other liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s change in other liabilities decreased by 98.1% year-over-year, from $1.95M to $36K.
- What does change in other liabilities mean?
- Change in miscellaneous liabilities affecting operating cash flow.